ClinicalTrials.gg
Sign In

Biological

Favezelimab/Pembrolizumab Formulation clinical trials

Also written MK-4280A.

studies test it
4
open now
1
in phase 3
1
first study started
2018

Keep track of what changes. Save the Favezelimab/Pembrolizumab Formulation studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.

Watch these studies

How studies write it

Studies that test it under each name

Name

coformulation favezelimab/pembrolizumab
2

Development codes

MK-4280A
4

Studies by the year they started

4 studies that test it; most in 2018 (1)

Studies that test Favezelimab/Pembrolizumab Formulation, by start year
YearStudies
20181
20211
20221
20231

By phase

A phase 1/2 study counts in both.

Phase 1
3
Phase 2
3
Phase 3
1

What it is tested for

Each study’s main condition, where its own words name it.

Small Cell Lung Carcinoma
1
Esophageal Squamous Cell Carcinoma
1
Hematologic Neoplasms
1

Who runs them

Industry 4 · Other 0

Merck Sharp & Dohme LLC (4)

Often tested with

Tested in the same studies.

Lenvatinib (2) · Pembrolizumab (2) · Pembrolizumab/Quavonlimab MK-1308A (1) · Anti-ILT4 Monoclonal Antibody MK-4830 (1) · Raludotatug deruxtecan (1) · Vibostolimab/Pembrolizumab MK-7684A (1) · Irinotecan (1) · Paclitaxel (1)

Studies

Open first, then newest update. How each study uses Favezelimab/Pembrolizumab Formulation is read from its arms, and is right about nine times in ten.

Testing it · 4

Given in every arm · 1 — Favezelimab/Pembrolizumab Formulation is usual care beside what is tested